Subsidiary of Beijing Wantai Biological Pharmacy Enterprise (603392.SH) has been selected to participate in the national immunization program vaccine centralized procurement project.

Beijing Wantai Biological Pharmacy Enterprise (603392.SH) announced that its wholly-owned subsidiary Xiamen Wantai Seascape Biotechnology Co., Ltd. participated in the bidding for the centralized procurement project for the bivalent human papillomavirus vaccine under the National Immunization Plan for 2025. The company's bivalent human papillomavirus vaccine (colibacillus) has been shortlisted. This centralized procurement project is organized by the Chinese Center for Disease Control and Prevention for the National Immunization Plan. If the company signs a procurement contract and organizes production and supply in the future, it will help expand the sales scale of the shortlisted products, increase market share, promote the development of the company's products in the domestic market, and enhance the company's brand influence.